Tormere Analytics
OverviewStock ResearchPortfolio LabOptions LabCalculatorsWatchlist
Data Explorer
Pricing
Privacy PolicyTerms of Service

AVLN

$34.67-7.84%

Avalyn Pharma Inc.

Market Cap
$1.6B
Sector
Materials
Industry
Pharmaceuticals
Beta
—
Insufficient price history
Price Chart
Loading…

Signals

Insider Velocity
25.6x
buying
Congress
—
recent trades
Short Volume
89%
W/W +15.7pp

Market & Alt Data

News
8
recent articles
Activist
13D
Avalyn
Analyst Consensus
Strong Buy
10 analysts
Velocity Score
25.65x
Current Rate (90d)
12345.67/mo
Baseline Rate
0.00/mo
Unique Buyers (90d)
3
Sort by
Type
Trade DateFiledOwnerRoleTypeSharesPriceValueOwned After
2026-05-012026-05-05Novo Holdings A/S10% OwnerPurchase555.6K$18.00$10.00M3.88MView
2026-05-012026-05-01Carroll JillDirectorPurchase277.8K$18.00$5.00M2.19MView
2026-05-012026-05-01SR ONE CAPITAL MANAGEMENT, LLC10% OwnerPurchase277.8K$18.00$5.00M1.12MView

Recent News

Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis
Yahoo Finance · 2026-09-08
Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Yahoo Finance · 2026-09-08
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026
Yahoo Finance · 2026-08-24
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Yahoo Finance · 2026-08-12

Informational purposes only, not investment advice.

What It Means To Hold Moderna Stock In A Crash
Yahoo Finance · 2026-07-13
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead
Yahoo Finance · 2026-06-06
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
Yahoo Finance · 2026-06-03
Avalyn to Participate in the Jefferies Global Healthcare Conference
Yahoo Finance · 2026-05-27

Factor Profile

Pro
Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro →
Pipeline
Phase 2
3 active trials · readout 2026-12